💊longevity compound protocol

Stage 1: C. elegans Testing

Initial Test

• If the compound does not reduce lifespan, and there is sufficient funds for fly testing, proceed to Fly Testing.

• If the compound reduces lifespan, proceed to Step 2.

Toxicity Mitigation

• Reduce the dosage or replicate the test.

• If both attempts (original dose + two follow-ups) confirm toxicity, terminate the compound.

• If an attempt shows non-toxicity (does not significantly reduce lifespan), proceed to Step 3.

Replication Requirement for Advancement

• Replicate the non-toxic result.

• If replication confirms non-toxicity, proceed to Stage 2.

• If replication fails, terminate the compound.

Financial Check

• If accrued fees are insufficient to pay for experiments, cannot proceed until there are sufficient funds.

Advancement Based on Mortality Milestones

• 50% Mortality: If there is a significant enrichment of the compound group over the control group, advance prior to the completion of the experiment.

• 75% Mortality: If there is a significant enrichment of the compound group over the control group, advance prior to the completion of the experiment.

• 90% Mortality: If there is a significant enrichment of the compound group over the control group, advance prior to the completion of the experiment.

• Otherwise, the full experiment must be completed, and the drug cannot significantly reduce maximum lifespan.

Stage 2: Fly Testing

Initial Test

• Use a dosage no more than 10x the dosage (mg/kg) of the C. elegans test.

• If the compound does not reduce lifespan, proceed to Stage 3.

• If the compound reduces lifespan, proceed to Step 2.

Toxicity Mitigation

• Modify one of the following:

  • Reduce dosage, change fly strain, or replicate test conditions

• Up to two attempts allowed:

  • If both confirm toxicity, terminate the compound.

  • If either attempt shows non-toxicity, proceed to Step 3.

Replication Requirement for Advancement

• Replicate the non-toxic result.

• If replication confirms non-toxicity, proceed to Stage 3.

• If replication fails, terminate the compound.

Financial Check

• If accrued fees are insufficient to pay for experiments, cannot proceed until there are sufficient funds.

Stage 3: Mouse Testing

Initial Test

• Use a dosage no more than 10x the dosage (mg/kg) of the fly test.

• If the compound does not hurt endurance, proceed to Stage 4.

• If the compound reduces endurance, proceed to Step 2.

Toxicity Mitigation

• Modify one of the following:

  • Reduce dosage, change mouse strain, or replicate test conditions

• Up to two attempts allowed:

  • If both confirm toxicity, terminate the compound.

  • If either attempt shows non-toxicity, proceed to Step 3.

Replication Requirement for Advancement

• Replicate the non-toxic result.

• If replication confirms non-toxicity, proceed to Stage 4.

• If replication fails, terminate the compound.

Financial Check

• If accrued fees are insufficient to pay for experiments, cannot proceed until there are sufficient funds.

Stage 4: Path to Humans

Compound Type Determination

• Natural product/supplement → Proceed to Supplement Path

• Everything else → Proceed to GRAS Path

Supplement Path

Conduct a Human Study

• If the compound shows no harm to biometrics (VO2max, sleep, etc), move forward to outlicense to manufacturers.

• If the compound significantly decreases maximum lifespan, proceed to Step 2.

Experiment Replication

• Choose one of the following:

  • Reduce the dosage or replicate the test.

• Up to two attempts allowed:

  • If both tests confirm negative biometric impact persists, terminate the compound.

  • If either test shows no harm, proceed to Step 3.

Replication Requirement for Advancement

• Replicate the result showing no negative impact to biometrics.

• If replication confirms no negative impact to biometrics, proceed to Step 4.

• If replication fails or there are insufficient funds, terminate the compound.

Non-Supplement Pathway

Conduct GRAS Studies

• Include toxicity and human studies.

• If non-toxic, outlicense for development.

• If toxic, terminate the compound.

Outlicense to Manufacturers

• The commercialization pathway begins once the compound is approved as a new food ingredient or new dietary ingredient, transitioning from scientific to commercial.

• If the compound is an approved dietary ingredient or food ingredient, it can be licensed to a manufacturer.